Biofrontera AG (FRA:B8FK)

Market Cap	15.31M +2.4%
Revenue (ttm)	13.19M -27.4%
Net Income	-7.10M
EPS	-1.19
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350
Average Volume	2
Open	2.510
Previous Close	2.520
Day's Range	2.510 - 2.590
52-Week Range	2.010 - 2.850
Beta	n/a
RSI	59.85
Earnings Date	Apr 17, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 76
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B8FK

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -7.10 million, 63.2% more than in 2024.